🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in the Netherlands / NCT07816458
Starting soon Phase 4

Alert-HF: Early Detection and Intervention on Atrial Fibrillation in Heart Failure Patients

NCT07816458 · tracked via the Priya Life Science Netherlands tracker
Phase
Phase 4
Started
2027-01
Last updated
2026-09-11

Condition(s) studied

Heart Failure

Investigational drug(s) / intervention(s)

Implantable loop recorderPatient-driven portable ECG monitoringUsual Care

Implantable loop recorder: Hospital-driven continuous monitoring with an implantable loop recorder

Patient-driven portable ECG monitoring: Patient-driven portable ECG monitoring

Usual Care: Usual care

Study summary

The goal of this clinical trial is to learn if using heart monitoring devices can lower unplanned hospital visits in adults with heart failure (HF). It focuses on adults with heart failure who have no history of an irregular heartbeat called atrial fibrillation (AF).

The main questions the trial aims to answer are:

Does a heart monitor placed under the skin lower unplanned hospital visits? Does a portable home device lower unplanned hospital visits?

Researchers will compare these two groups to a standard care group to see which monitoring approach works best.

Participants will:

Answer a health survey at the start of the study and after 18 months. Have a small heart monitor placed under their chest skin to watch their heart rhythm, if they are in the first group.

Use a handheld device to take weekly heart readings at home, if they are in the second group.

Follow standard care from their regular doctor without any extra devices, if they are in the third group.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult patients with HF and no history of documented AF on electrocardiogram (ECG) are eligible. Exclusion Criteria: * Patients with CIED such as an implantable cardioverter defibrillator (ICD), Cardiac Resyn-chronization Therapy Defibrillator (CRT-D), or pacemaker. * Documented AF before inclusion * Admission to hospices or palliative care * Inability to communicate in Dutch or English. * Participant is under age of 18 years old * Participant is pregnant * Mental disorders that, according to the treating physician, make participation unsafe

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Medisch Spectrum Twente Enschede Netherlands

More Medisch Spectrum Twente trials in the Netherlands

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07816458 on ClinicalTrials.gov ↗ ← All trials in the Netherlands